We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed (RMD) Rallies as Philips Falters on Mass Product Recall
Read MoreHide Full Article
Shares of ResMed (RMD - Free Report) rose 6% to reach $231.70 after the company’s peer in the field of sleep apnea devices, Koninklijke Philips (PHG - Free Report) issued recall notification for a series of its sleep and respiratory care devices. Many of the analysts think that Philips being in a tight spot will lead to a shift in customer demand toward ResMed competitive products.
Shares of Philips dropped nearly 4% following the announcement.
More About the News
Philips yesterday noted that its recall notification was to voluntarily withdraw specific Philips Bi-Level Positive Airway Pressure (Bi-Level PAP), Continuous Positive Airway Pressure (CPAP) and mechanical ventilator devices. This voluntary recall decision was to address identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam component in these devices.
Image Source: Zacks Investment Research
According to Philips, majority of the affected devices, which are within the advised five-year service life fall under the first-generation DreamStation product family. The company noted that to date it has produced millions of Bi-Level PAP, CPAP and mechanical ventilator devices using the PE-PUR sound abatement foam.
Per a Reuters report, Philips chief executive Frans van Houten noted that between 3 million and 4 million devices would be targeted in the recall. Company spokesman Steve Klink said about 80% of the affected devices were CPAP machines and the other 20% of affected devices were ventilators.
ResMed to Enjoy Strong Peer Position
According to The Street report, Needham analyst Mike Matson noted that the repairs of these devices will likely take at least several months. In this period, some patients using the Philips ventilators might shift to ResMed. He also stated that users with insurance coverage can substitute a ResMed device for their Royal Philips device, if that device is older than five years.
In this regard, we note that the sleep and respiratory care of ResMed includes Device, and Masks and other. Devices include CPAP, variable positive airway pressure (VPAP) and AutoSet systems for the titration and treatment of SDB. The Masks and others portfolio consists of different masks for sleep-disordered breathing (SDB) treatments like AirFit F20 in the full-face category and the AirFit N20, AirFit N30i, AirTouch N20 etc.
Our Take
We note that Philips Respironics DreamStation directly competes with the ResMed AirSense 10. ResMed recently started a limited controlled product launch of the AirSense 11 flow generator in certain parts of the United States. The full U.S. launch is expected in late 2021, which might receive bigger market acceptance capitalizing on its current competitive position.
Share Price Performance of RMD
In the past three months, ResMed has outperformed its industry. The stock has gained 23.8% against 1.9% dip of the industry.
Currently, the company carries a Zacks Rank #3 (Hold).
Envista Holdings has an estimated long-term earnings growth rate of 26%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
ResMed (RMD) Rallies as Philips Falters on Mass Product Recall
Shares of ResMed (RMD - Free Report) rose 6% to reach $231.70 after the company’s peer in the field of sleep apnea devices, Koninklijke Philips (PHG - Free Report) issued recall notification for a series of its sleep and respiratory care devices. Many of the analysts think that Philips being in a tight spot will lead to a shift in customer demand toward ResMed competitive products.
Shares of Philips dropped nearly 4% following the announcement.
More About the News
Philips yesterday noted that its recall notification was to voluntarily withdraw specific Philips Bi-Level Positive Airway Pressure (Bi-Level PAP), Continuous Positive Airway Pressure (CPAP) and mechanical ventilator devices. This voluntary recall decision was to address identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam component in these devices.
According to Philips, majority of the affected devices, which are within the advised five-year service life fall under the first-generation DreamStation product family. The company noted that to date it has produced millions of Bi-Level PAP, CPAP and mechanical ventilator devices using the PE-PUR sound abatement foam.
Per a Reuters report, Philips chief executive Frans van Houten noted that between 3 million and 4 million devices would be targeted in the recall. Company spokesman Steve Klink said about 80% of the affected devices were CPAP machines and the other 20% of affected devices were ventilators.
ResMed to Enjoy Strong Peer Position
According to The Street report, Needham analyst Mike Matson noted that the repairs of these devices will likely take at least several months. In this period, some patients using the Philips ventilators might shift to ResMed. He also stated that users with insurance coverage can substitute a ResMed device for their Royal Philips device, if that device is older than five years.
In this regard, we note that the sleep and respiratory care of ResMed includes Device, and Masks and other. Devices include CPAP, variable positive airway pressure (VPAP) and AutoSet systems for the titration and treatment of SDB. The Masks and others portfolio consists of different masks for sleep-disordered breathing (SDB) treatments like AirFit F20 in the full-face category and the AirFit N20, AirFit N30i, AirTouch N20 etc.
Our Take
We note that Philips Respironics DreamStation directly competes with the ResMed AirSense 10. ResMed recently started a limited controlled product launch of the AirSense 11 flow generator in certain parts of the United States. The full U.S. launch is expected in late 2021, which might receive bigger market acceptance capitalizing on its current competitive position.
Share Price Performance of RMD
In the past three months, ResMed has outperformed its industry. The stock has gained 23.8% against 1.9% dip of the industry.
Currently, the company carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Envista Holdings Corporation (NVST - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>